TABLE 1.
Clinical trials of metabolic intervention of COVID‐19
| Drug | Metabolic target | Clinical trial number | Phase | Status | Drug type |
|---|---|---|---|---|---|
| PEA 235 |
Lipid metabolism (PPAR‐α) |
NCT04619706 | 2 | Terminated | Chemical |
| NCT04568876 | 4 | Completed | |||
| Pioglitazone 249 |
Lipid metabolism (PPAR‐γ) |
NCT04535700 | 4 | Recruiting | Chemical |
| Baricitinib 236 |
Fatty acid metabolism (JAK1/JAK2) |
NCT04421027 | 3 | Completed | Chemical |
| Fenofibrate 237 | Cholesterol metabolism | NCT04517396 | 2 | Completed | Chemical |
| VPA 250 |
Glucose metabolism (HDAC) |
NCT04513314 | 4 | Not yet recruiting | Chemical |
| Masitinib 240 |
Potentially glucose metabolism (Tyrosine kinase) |
NCT05047783 | 2 | Recruiting | Chemical |
| Methotrexate 251 | Folate metabolism | NCT04610567 | 1 | Recruiting | Chemical |
| Cholecalciferol 252 | Steroid metabolism | NCT04952857 | 4 | Completed | Chemical |
| Nicotinamide 253 | Nicotinamide metabolism | NCT04751604 | NA | Active, not recruiting | Chemical |
| L‐citrulline 254 | Amino acid metabolism | NCT04404426 | NA | Completed | Chemical |
| Coenzyme Q10 255 | Mitochondrial metabolism | NCT04960215 | 2 | Completed | Chemical |